Stockscreener 앱 받기
231.25
3.78%
-9.09
전일 마감가:
$240.34
열려 있는:
$239.35
하루 거래량:
1.46M
Relative Volume:
1.09
시가총액:
$32.25B
수익:
$2.12B
순이익/손실:
$-309.19M
주가수익비율:
-101.24
EPS:
-2.2841
순현금흐름:
$93.57M
1주 성능:
-1.31%
1개월 성능:
+1.69%
6개월 성능:
+55.83%
1년 성능:
+37.24%
1일 변동 폭
$230.13
$241.00
1주일 범위
$226.12
$243.47
52주 변동 폭
$125.38
$256.36
Natera Inc Stock (NTRA) Company Profile
명칭
Natera Inc
전화
650-249-9090
주소
13011 MCCALLEN PASS, AUSTIN, CA
NTRA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
231.25 | 33.52B | 2.12B | -309.19M | 93.57M | -2.2841 |
|
TMO
Thermo Fisher Scientific Inc
|
618.72 | 234.69B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
235.99 | 169.45B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
715.37 | 56.86B | 4.17B | 1.03B | 940.22M | 12.61 |
|
IQV
Iqvia Holdings Inc
|
237.68 | 41.09B | 15.90B | 1.28B | 2.21B | 7.2842 |
|
A
Agilent Technologies Inc
|
139.64 | 41.06B | 6.95B | 1.30B | 1.15B | 4.5696 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-07 | 개시 | Citigroup | Buy |
| 2025-12-02 | 재개 | Morgan Stanley | Overweight |
| 2025-10-27 | 업그레이드 | BNP Paribas Exane | Underperform → Neutral |
| 2025-09-22 | 재개 | Wells Fargo | Equal Weight |
| 2025-03-13 | 개시 | RBC Capital Mkts | Outperform |
| 2025-01-23 | 개시 | Barclays | Overweight |
| 2024-06-03 | 재개 | Jefferies | Buy |
| 2024-04-08 | 재개 | Craig Hallum | Buy |
| 2024-02-20 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2023-12-29 | 재확인 | BTIG Research | Buy |
| 2023-12-14 | 개시 | Guggenheim | Buy |
| 2023-12-13 | 개시 | Wolfe Research | Outperform |
| 2023-11-13 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-09-28 | 개시 | Bernstein | Mkt Perform |
| 2023-07-05 | 재개 | JP Morgan | Overweight |
| 2023-05-05 | 개시 | UBS | Buy |
| 2023-01-18 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-04-25 | 개시 | Stephens | Overweight |
| 2022-03-08 | 개시 | Goldman | Buy |
| 2022-01-06 | 재개 | Piper Sandler | Overweight |
| 2021-10-15 | 재개 | Cowen | Outperform |
| 2021-06-15 | 개시 | Raymond James | Mkt Perform |
| 2021-05-25 | 개시 | Wells Fargo | Overweight |
| 2021-01-28 | 개시 | Truist | Buy |
| 2020-10-08 | 개시 | BTIG Research | Buy |
| 2020-09-28 | 개시 | Morgan Stanley | Overweight |
| 2020-09-17 | 개시 | SVB Leerink | Outperform |
| 2020-06-10 | 재개 | Piper Sandler | Overweight |
| 2020-05-07 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-10-05 | 개시 | JP Morgan | Neutral |
| 2018-07-05 | 재확인 | Piper Jaffray | Overweight |
| 2017-08-07 | 재확인 | Morgan Stanley | Overweight |
| 2016-11-10 | 재확인 | The Benchmark Company | Buy |
| 2016-05-23 | 재확인 | The Benchmark Company | Buy |
| 2016-05-11 | 재확인 | The Benchmark Company | Buy |
| 2016-04-19 | 개시 | The Benchmark Company | Buy |
| 2015-09-28 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2015-08-14 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2015-08-04 | 개시 | Robert W. Baird | Outperform |
| 2015-07-27 | 개시 | Morgan Stanley | Equal-Weight |
| 2015-07-27 | 개시 | Piper Jaffray | Overweight |
| 2015-07-27 | 개시 | Wedbush | Neutral |
모두보기
Natera Inc 주식(NTRA)의 최신 뉴스
Natera prenatal test false advertising $8.25M class action settlement explained: Are you owed money? - Claim Depot
AI-Enhanced Signatera Upgrade And NVIDIA Deal Could Be A Game Changer For Natera (NTRA) - simplywall.st
Is It Too Late To Consider Natera (NTRA) After Its Strong 1-Year Share Price Run? - simplywall.st
Natera Targets Endometrial Cancer With New Signatera Trial, Expanding Its MRD Opportunity - TipRanks
Sumitomo Mitsui Trust Group Inc. Sells 88,968 Shares of Natera, Inc. $NTRA - MarketBeat
Assessing Whether Natera (NTRA) Is Overvalued After Strong Longer Term Share Price Gains - Yahoo Finance
Natera unveils AI model to enhance cancer recurrence risk assessment By Investing.com - Investing.com Nigeria
How Investors Are Reacting To Natera (NTRA) NVIDIA-Backed Multimodal AI And Precision Diagnostics Advances - Yahoo Finance
Natera’s SCORE Study Builds Real-World Evidence for Cancer MRD Testing - TipRanks
NTRA & NVDA Partner to Improve AI Models for Precision Medicine - Nasdaq
Natera, Inc. Announces Next Breakthrough in MRD-Based Risk Stratification, Leveraging Multi-Modal AI Modeling - marketscreener.com
Natera unveils AI model to enhance cancer recurrence risk assessment - Investing.com
Natera Announces Next Breakthrough in MRD-Based Risk Stratification, Leveraging Multi-Modal AI Modeling - Yahoo Finance
Natera: Accelerating MRD Momentum, Revenue Outperformance, and Improving Cash Profile Support Buy Rating - TipRanks
(NTRA) and the Role of Price-Sensitive Allocations - Stock Traders Daily
JP Morgan lifts Natera, Inc. (NTRA) target on Signatera momentum - MSN
Natera’s updated prenatal test, Fetal Focus, adds Gaucher disease - Gaucher Disease News
Natera (NTRA) Joins Forces with NVIDIA to Boost AI in Precision Medicine - GuruFocus
Nvidia enters collaboration with Natera - TipRanks
Natera to Scale AI Foundation Models in Precision Medicine with NVIDIA - marketscreener.com
MarketsMedicine Hat News - FinancialContent
Natera stock rises as Canaccord maintains Buy rating on strong preliminary results - Investing.com Nigeria
Natera stock rises as Canaccord maintains Buy rating on strong preliminary results By Investing.com - Investing.com South Africa
Natera (NTRA) Reports Robust Q4 and FY 2025 Revenue Growth - GuruFocus
Natera Q4 Preliminary Revenue Rises; Shares Up Pre-Bell - marketscreener.com
Natera Announces Strong Preliminary Fourth Quarter and 2025 Financial Results Driven by Record Signatera™ Growth - BioSpace
NTRA Reports Strong FY25 Revenue and Test Volume Growth - GuruFocus
Natera Q4 prelim revenue beats on oncology tests boost - TradingView — Track All Markets
Natera Reports Preliminary Q4 2025 Results, Record Year for Oncology Testing - Intellectia AI
Breakeven On The Horizon For Natera, Inc. (NASDAQ:NTRA) - Yahoo Finance
Natera, Inc.'s (NASDAQ:NTRA) Business Is Yet to Catch Up With Its Share Price - 富途牛牛
Natera (NASDAQ:NTRA) Stock Rating Upgraded by Citigroup - MarketBeat
Market Catalysts: Is Natera Inc. stock attractive after correctionWatch List & Consistent Income Trade Ideas - Улправда
Natera (NTRA) announces publication of findings from randomized, phase III CALGB (Alliance)/SWOG 80702 study - MSN
Non-Invasive Prenatal Testing Market is expected to generate a revenue of USD 9.83 Billion by 2031, Globally, at 17.01% CAGR: Verified Market Research® - GlobeNewswire Inc.
Natera, Inc. $NTRA Shares Acquired by SG Americas Securities LLC - MarketBeat
How Natera ctDNA Partnership Around STELLAR-316 At Exelixis (EXEL) Has Changed Its Investment Story - Yahoo Finance
Will Natera Inc. stock outperform tech sector in 2025Insider Buying & Real-Time Stock Entry Alerts - ulpravda.ru
Can Natera Inc. stock sustain market leadership2025 AllTime Highs & Risk Controlled Stock Pick Alerts - ulpravda.ru
Is Natera Inc. stock attractive for growth ETFs2025 Top Gainers & Free High Accuracy Swing Entry Alerts - ulpravda.ru
NTRANatera Inc Latest Stock News & Market Updates - Stock Titan
Natera (NASDAQ:NTRA) Shares Down 7.6%What's Next? - MarketBeat
Will Natera Inc. stock gain from strong economyQuarterly Portfolio Report & Risk Adjusted Buy/Sell Alerts - Улправда
Can Natera Inc. stock weather global recessionJuly 2025 Momentum & Reliable Entry Point Alerts - ulpravda.ru
Can Natera Inc. stock beat analyst upgradesJuly 2025 Opening Moves & Real-Time Chart Pattern Alerts - ulpravda.ru
EXEL Collaborates With Natera for Late-Stage Colorectal Cancer Study - Finviz
Exelixis and Natera to collaborate on MRD-guided cancer trial By Investing.com - Investing.com Nigeria
Citigroup Initiates Buy Rating on Natera (NTRA) with $300 Price Target | NTRA Stock News - GuruFocus
Assessing Natera (NTRA) Valuation After Positive ALTAIR Trial Data And Expanded Fetal Focus Test Launch - simplywall.st
Medical stock hovers near buy point after 46% gain - MSN
Why Natera’s Stock Is Sliding Despite Bullish Outlook - TipRanks
Natera Inc (NTRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Natera Inc 주식 (NTRA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Moshkevich Solomon | PRESIDENT, CLINICALDIAGNOSTICS |
Jan 02 '26 |
Sale |
228.95 |
2,951 |
675,621 |
123,499 |
| Chapman Steven Leonard | CEO AND PRESIDENT |
Jan 02 '26 |
Sale |
229.08 |
3,848 |
881,482 |
136,568 |
2.40%
0.74%
자본화:
|
볼륨(24시간):